WHWilliam G. Helferich

William G. Helferich

*This is an algorithmically generated author record based on publicly available information.

William G. Helferich has a total of 24 co-authors. Here are the top co-authors by number of shared publications:

  • Young H. Ju

    Department of Human Nutrition, Foods and Exercise, Virginia Polytechnic Institute and State University, Blacksburg, VA, USA

    5 shared publications
  • Daniel R. Doerge

    Division of Biochemical Toxicology, National Center for Toxicological Research, U.S. Food and Drug Administration, Jefferson, AR, USA

    4 shared publications
  • Kimberly F. Allred

    Department of Food Science and Human Nutrition University of Illinois 905 S Goodwin Room 580 Bevier Hall Urbana IL USA

    3 shared publications
  • Clinton D. Allred

    Department of Food Science and Human Nutrition University of Illinois 905 S Goodwin Room 580 Bevier Hall Urbana IL USA

    2 shared publications
  • Afia Naaz

    Departments of Veterinary Biosciences, University of Illinois at Urbana-Champaign, Urbana, Illinois 61802

    1 shared publication
  • D. R. Doerge

    Division of Biochemical Toxicology FDA, National Center for Toxicological Research, Jefferson, AR 72079, USA

    1 shared publication

Latest Publications

  • Open Access

    Low-dose dietary genistein negates the therapeutic effect of tamoxifen in athymic nude mice

    by Mengyuan Du, Xujuan Yang, James A. Hartman, Paul S. Cooke, Daniel R. Doerge, Young H. Ju, William G. Helferich

    The present study examined the effect of dietary genistein, a soy isoflavone, on breast cancer patients who take tamoxifen, an antiestrogen treatment, using a preclinical model. The interaction of various doses of genistein with tamoxifen on the growth of estrogen receptor-positive breast cancer MCF-7 cells was investigated by subcutaneously injecting MCF-7 cells into the flank of ovariectomized athymic mice. Animals were randomized into eight experimental groups with 10–13 mice per group: control (C), estrogen (E) (0.08 mg E implant), tamoxifen (T) (3 mg T implant), estrogen + tamoxifen (E + T), tamoxifen + 500 p.p.m. genistein (T + G500), estrogen + tamoxifen + 250 p.p.m. genistein (E + T + G250), estrogen + tamoxifen + 500 p.p.m. genistein (E + T + G500) and estrogen + tamoxifen + 1000 p.p.m. genistein (E + T + G1000). Treatment of tamoxifen significantly reduced the estrogen-induced MCF-7 tumor prevalence and tumor size. This inhibitory effect of tamoxifen was significantly negated by the low doses of dietary genistein (250 and 500 p.p.m.), whereas the 1000 p.p.m. genistein did not have the same effect. Cells harvested from tamoxifen-treated tumors retained estrogen responsiveness of their progenitor MCF-7 cells, indicating that the abrogating effect of genistein on tamoxifen-treated tumor growth was not caused by a diminished tamoxifen response but directly by genistein. The low doses of dietary genistein abrogated the inhibitory effect of tamoxifen potentially by acting on the tumor cell proliferation/apoptosis ratio and the messenger RNA (mRNA) expression of cyclin D1 in addition to regulating the mRNA expression of progesterone receptor. Therefore, data from the current study suggest that caution is warranted regarding the consumption of dietary genistein by breast cancer patients while on tamoxifen therapy.


  • Absolute Bioavailability of Isoflavones from Soy Protein Isolate-Containing Food in Female Balb/c Mice

    by Juan E. Andrade, Nathan C. Twaddle, William G. Helferich, Daniel R. Doerge

    Soy isoflavones, genistein and daidzein, are widely consumed in soy-based foods and dietary supplements for their putative health benefits; however, evidence for potential adverse effects has been obtained from experimental animal studies. An important prerequisite for understanding the pharmacodynamics of isoflavones is better information about pharmacokinetics and bioavailability. This study determined the bioavailability of genistein and daidzein in a mouse model by comparing plasma pharmacokinetics of their aglycone and conjugated forms following administration of identical doses (1.2 mg/kg genistein and 0.55 mg/kg daidzein) by either an intravenous injection (IV) or gavage of the aglycones in 90% aqueous solution vs a bolus administration of equimolar doses delivered in a food pellet prepared using commercial soy protein isolate (SPI) as the isoflavone source. The bioavailability of genistein and daidzein was equivalent for the gavage and dietary routes of administration despite the use of isoflavone aglycones in the former and SPI-derived glucosides in the latter. While absorption of total isoflavones was nearly quantitative from both oral routes [>84% of areas under the curve (AUCs) for IV], presystemic and systemic phase II conjugation greatly attenuated internal exposures to the receptor-active aglycone isoflavones (9−14% for genistein and 29−34% for daidzein based on AUCs for IV). These results show that SPI is an efficient isoflavone delivery vehicle capable of providing significant proportions of the total dose into the circulation in the active aglycone form for distribution to receptor-bearing tissues and subsequent pharmacological effects that determine possible health benefits and/or risks.


  • Dietary genistein negates the inhibitory effect of letrozole on the growth of aromatase-expressing estrogen-dependent human breast cancer cells (MCF-7Ca) in vivo

    by Y. H. Ju, D. R. Doerge, K. A. Woodling, J. A. Hartman, J. Kwak, W. G. Helferich

    Genistein (GEN), a soy isoflavone, stimulates growth of estrogen-dependent human tumor cells (MCF-7) in a preclinical mouse model for postmenopausal breast cancer. Antiestrogens and aromatase inhibitors are frontline therapies for estrogen-dependent breast cancer. We have demonstrated that dietary GEN can negate the inhibitory effect of tamoxifen. In this study, we evaluated the interaction of dietary GEN (at 250-1000 p.p.m. in the American Institute of Nutrition 93 growth diet) and an aromatase inhibitor, letrozole (LET), on the growth of tumors in an aromatase-expressing breast cancer xenograft model (MCF-7Ca) in the presence and absence of the substrate androstenedione (AD). Dietary GEN (250 and 500 p.p.m.) or implanted AD stimulated MCF-7Ca tumor growth. Implanted LET inhibited AD-stimulated MCF-7Ca tumor growth. In the presence of AD and LET, dietary GEN (250, 500 and 1000 p.p.m.) reversed the inhibitory effect of LET in a dose-dependent manner. Uterine wet weight, plasma estradiol (E(2)) levels (enzyme-linked immunosorbent assay) and total plasma GEN and LET levels (liquid chromatography-electrospray/tandem mass spectrometry) were measured. Ki-67 (cellular proliferation), aromatase and pS2 protein expression in tumors were evaluated using immunohistochemical (IHC) analysis. In conclusion, dietary GEN increased the growth of MCF-7Ca tumors implanted in ovariectomized mice and could also negate the inhibitory effect of LET on MCF-7Ca tumor growth. These findings are significant because tumors, which express aromatase and synthesize estrogen, are good candidates for aromatase therapy dietary and GEN can reverse the inhibitory effect of LET on tumor growth and adversely impact breast cancer therapy. Caution is warranted for consumption of dietary GEN by postmenopausal women with estrogen-dependent breast cancer taking LET treatment.


  • Open Access

    Genistein stimulates growth of human breast cancer cells in a novel, postmenopausal animal model, with low plasma estradiol concentrations

    by Young H. Ju, Kimberly F. Allred, Clinton D. Allred, William G. Helferich

    We have demonstrated that genistein (GEN) stimulates growth of estrogen-dependent breast tumors in vivo . In this study, we evaluated whether dietary GEN can act in an additive manner with low circulating levels of 17β-estradiol (E 2 ). We developed an E 2 delivery system using silastic implants that yield low circulating plasma E 2 levels similar to those observed in postmenopausal women. We inserted various concentrations of E 2 silastic implants (1:127, 1:63, 1:31, 1:15 and 1:7 = E 2 :cholesterol) and injected estrogen-dependent human breast cancer (MCF-7) cells into ovariectomized athymic mice. The E 2 implants tested (1:127–1:7) generated 30.1–101.6 pM E 2 in plasma, which is comparable to the E 2 levels observed in postmenopausal women. The E 2 implants stimulated MCF-7 tumor growth in a dose-dependent manner. We selected the 1:31 ratio of E 2 implant to evaluate if dietary GEN acts in an additive manner with low E 2 levels to influence the growth of MCF-7 tumors. Ovariectomized mice were divided into four groups: MCF-7 control, 500 ppm GEN, 1:31 E 2 , and 1:31 E 2 + 500 ppm GEN. At week 17, the average tumor sizes were 7.6, 32.1, 67.4 and 106.8 mm 2 for these groups, respectively ( P < 0.05), demonstrating that 500 ppm GEN additively stimulated MCF-7 tumor growth in the presence of low levels of E 2 . In summary, we established a preclinical mouse model that results in E 2 blood concentrations similar to those found in postmenopausal women. Further, we observed that these concentrations regulate the growth rate of MCF-7 breast tumors. Using this model, we demonstrated that dietary GEN in the presence of low levels of circulating E 2 act in an additive manner to stimulate estrogen-dependent tumor growth in vivo . Results from this study suggest that consumption of products containing GEN may not be safe for postmenopausal women with estrogen-dependent breast cancer.


  • Open Access

    Effects of dietary daidzein and its metabolite, equol, at physiological concentrations on the growth of estrogen-dependent human breast cancer (MCF-7) tumors implanted in ovariectomized athymic mice

    by Young H. Ju, Jodi Fultz, Kimberly F. Allred, Daniel R. Doerge, William G. Helferich

    Genistein and daidzein are the main isoflavones in legumes. Equol is an intestinal bacterial metabolite of daidzein. In this study, we evaluated the estrogenic potential of daidzein and synthetic (±)-equol to stimulate growth of estrogen-dependent breast cancer (MCF-7) in vitro and in vivo . We hypothesize that estrogenic effects of daidzein and (±)-equol could modulate the growth of MCF-7 cells both in vitro and also once implanted into ovariectomized athymic mice. At concentrations between 0.001 and 50 μM, daidzein and (±)-equol stimulated the growth of MCF-7 cells with maximal stimulation at 1 μM in vitro . To evaluate their effects on the growth of MCF-7 cells implanted in ovariectomized athymic mice, two dietary dose–response studies [daidzein (125, 250, 500 and 1000 p.p.m.) and (±)-equol (250, 500 and 1000 p.p.m.)] were conducted. Tumor size and body weight were monitored weekly during the study. At completion of the study, we analyzed cellular proliferation of tumors using immunohistochemical staining (ki-67), pS2 expression in tumors using a real time quantitative reverse transcription–polymerase chain reaction (qRT–PCR), and total daidzein and (±)-equol levels in plasma using liquid chromatography–electrospray tandem mass spectrometry (LC–ES/MS/MS). Dietary daidzein had a slight but significant stimulatory effect on MCF-7 tumor growth in mice. No significant induction of pS2 mRNA (an estrogen-responsive marker) in tumors by dietary daidzein was observed. Total plasma daidzein concentrations in plasma were between 0.25 and 1.52 μM. Dietary equol treatment (for 37 weeks) did not stimulate MCF-7 tumor growth. There were no statistical differences in tumor size, proliferation and pS2 expression among any treatment groups. Total equol concentrations in plasma were 2.10–3.21 μM. In conclusion, daidzein and (±)-equol have proliferative effects on MCF-7 cell growth in vitro within the concentration range tested. Dietary daidzein had a slight but significant stimulatory effect on tumor growth, whereas (±)-equol did not stimulate the growth of estrogen-dependent breast tumor growth in athymic mice, increase the cell proliferation in tumors, or induce an estrogen-responsive pS2 expression. Total daidzein or (±)-equol plasma levels in mice fed the isoflavones were in the range that stimulated MCF-7 cell growth in vitro . These results suggest that pharmacokinetic and/or metabolic factors attenuate the estrogenic effects of daidzein and equol in vivo .


  • Open Access

    Estrogenicity of the Isoflavone Metabolite Equol on Reproductive and Non-Reproductive Organs in Mice1

    by Vimal Selvaraj, Melissa A. Zakroczymski, Afia Naaz, Motoko Mukai, Young H. Ju, Daniel R. Doerge, John A. Katzenellenbogen, William G. Helferich, Paul S. Cooke

    Equol, a metabolite of the phytoestrogen daidzein, is present at significant levels in some humans who consume soy and in rodents fed soy-based diets


  • Open Access

    Physiological Concentrations of Dietary Genistein Dose-Dependently Stimulate Growth of Estrogen-Dependent Human Breast Cancer (MCF-7) Tumors Implanted in Athymic Nude Mice

    by Young H. Ju, Clinton D. Allred, Kimberly F. Allred, Kimberly L. Karko, Daniel R. Doerge, William G. Helferich

    Previously our laboratory has shown that the soy isoflavone, genistein, stimulates growth of human breast cancer (MCF-7) cells in vivo and in vitro. In this study, the dose-response analysis of genistein at the physiologically achievable concentration range between 125 and 1,000 μg/g in the diet was conducted in ovariectomized athymic nude mice implanted with MCF-7 cells. We hypothesized that genistein at this concentration range can stimulate dose-dependently the breast tumor growth, cell proliferation and an estrogen-responsive pS2 gene induction. Tumor size and body weight were monitored weekly. At completion of the study, we analyzed cellular proliferation of tumors using incorporation of BrdU, pS2 expression of tumors using a Northern blot analysis and total genistein level in plasma using liquid chromatography–isotope dilution mass spectrometry (LC-ES/MS). Dietary genistein (≥250 μg/g) increased tumor size in a dose-dependent manner [8.4× the negative control (NC) group in the 250 μg/g group, 12.0× in the 500 μg/g group, 20.2× in the 1,000 μg/g group and 23.2× in the positive control (PC) group]. The percentage of proliferating cells was significantly increased by genistein at and above 250 μg/g (5.3× the NC group in the 250 μg/g, 5.6× in the 500 μg/g, 5.0× in the 1,000 μg/g and 4.8× in the PC group). Expression of pS2 mRNA was also significantly increased with increasing dietary genistein levels (11.25× the NC group in the 500 μg/g group and 15.84× in the 1,000 μg/g group). Total plasma genistein concentrations were between 0.39 and 3.36 μmol/L in mice fed between 125 and 1,000 μg/g genistein. In conclusion, dietary treatment with genistein at physiological concentrations produces blood levels of genistein sufficient to stimulate estrogenic effects, such as breast tumor growth, cellular proliferation and pS2 expression in athymic mice in a dose-responsive manner similar to that seen in vitro.